Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
JEFFERIES uniQure N.V. (QURE): Update from Meeting with QURE Management Rating BUY Price Target $36.00 Price $16.35 Bloomberg NASDAQ: QURE *Shares Out. (MM): Reflects share balance as of 9/30/15Key Takeaway For 2016, we view clinical data catalysts to be on AMT-060 for hemophilia B. QURE expects additional 3 pts Ph1/2 data for AMT-060 low-dose cohort to be presented at a medical conference in 2Q16 and data from high-dose cohort (4x low-dose) potentially by YE16. On non-human primate data, QURE expects higher F9 expression (vs. 4.5-5.5% observed at low-dose in n=2), although not commenting on an anticipated magnitude of F9 expression. For AMT-060 for hemophilia B (human Factor IX [FIX] gene in an AAV5 vector), enrollment in high-dose cohort (2x10^13 gc/kg, over 4x low-dose; n=~5) in Ph1/2 to begin in ~1Q16 following a DMC meeting in ~early-Feb. with a potential update by YE16. Based on non-human primate data, QURE expects high-dose AMT-060 to produce higher F9 expression vs. the low-dose (~4.5-5.5% in n=2), although not commenting on the magnitude of anticipated increases. Given that potential liver toxicity is correlated to the high vector copy numbers, QURE recently amended the protocol for high-dose cohort to require 2x weekly liver enzyme screening in the first 12 wks tx and recommend prednisolone administration for ALT levels >1.5-2.0x baseline. QURE will also allow enrollment of >5 pts, noting high interests from patients seen to date. Final design of pivotal trial, expected to begin in 2017, is yet to be discussed; QURE has noted an open-label trial of ~40-50 pts with primary endpoints such as annual bleed rate (ABR) and PK as possible. Additional 3 pts in AMT-600 low-dose cohort (5x10^12 gc/kg) in Ph1/2 to be presented at a medical conference in 2Q16, potentially at World Federation of Hemophilia in Orlando, FL on 7/24-7/28/16 or European Hematology Association in Copenhagen, Denmark on 6/9-6/12/16. On 1/7/16, preliminary topline results from 2 pts in the low-dose cohort showed F9 expression of 5.5%/4.5% at ~20/12 wks of follow-up post treatment (vs. <1-2% prior to tx), validating ability of QURE's AAV5 vector to penetrate the liver. As of 1/6/16, all 5 pts had completed at least 10 wks of therapy and n=4/5 pts had discontinued prophylactic recombinant F9 therapy (a secondary endpoint for the trial). No patients developed antibodies against AAV5; the first pt treated experienced a mild, transient and asymptomatic ALT elevation at ~10 wks post tx, which resolved following 8 wks of tapering prednisolone doses. In a St. Jude's study utilizing the same F9 gene cassette (scAAV2/8-LP1-hFIXco; at the same dose as AMT low-dose, 2x10^12 vector genome/kg) in an AAV8 vector, n=4/7 pts were able to discontinue prophylactic rF9 therapy with F9 levels of up to ~7% of normal. Sustained F9 levels of the pts who could not discontinue prophylactic therapy were ~1-3%. Upcoming events include: (1) full low-dose Ph1/2 data (n=5) for AMT-060 in hemophilia B at a medical meeting in 2Q16 (potentially World Federation of Hemophilia on 7/24-7/28/16 or European Hematology Association on 6/9-6/12/16); ?(2) regulatory pathway for AMT-060 & AMT-110 to be established in 2016; (3) potential Ph1/2 high-dose data for AMT-060 in hemophilia B by YE16; (4) IND-enabling studies for Huntington's Disease & hemophilia A to begin in 2016; (5) at least 1 new program each in liver & CNS to be nominated in 2016; and (6) 30-month follow-up data for AMT-110 in Sanfilippo B in early-2017.
There is excitement in the hemophilia community, both from the side of patients and from physicians and researchers, about the potential benefits of gene therapy for the health and quality of life of hemophiliacs. The potential that a successful gene therapy would allow hemophiliacs to forego prophylactic treatment in the future would be life changing.
T. Montana schreef op 13 januari 2016 13:57 :
JEFFERIES
uniQure N.V. (QURE): Update from Meeting with QURE Management
Rating BUY
Price Target $36.00
Price $16.35
Bloomberg NASDAQ: QURE
[..]
Prrrr, het wordt steeds erger... "30-month follow-up data for AMT-110 in Sanfilippo B in early-2017." Tijdens de Investor Day is eind 2016 aangegeven! Worden de resultaten dan gepresenteerd tijdens JPM17? Een goedmakertje? En wat is de implicatie voor de beoogde pivotal trial? Ook uitstel? Over tweede cohort Hemofilie B: "data from high-dose cohort (4x low-dose) potentially by YE16" "with a potential update by YE16" Het rekensommetje leert dat ze in november/december van hooguit 3 patiënten de zogeheten topline resultaten kunnen presenteren. En dat er op de ASH door QURE niks gepresenteerd zal worden (of het moeten deze resultaten zijn). "QURE will also allow enrollment of >5 pts, noting high interests from patients seen to date." Hoe moeten we de bijzin "noting high interests" lezen? Ik neem toch aan dat er een bedrijfsstrategie achter zit. Verkorten DMC reviewtijd in trial?
Voor een nieuwe CEO is nu wsch het beste moment om de timelines wat voorzichtiger in de markt te zetten. Eerlijk gezegd word ik er niet koud of warm van. In deze biz zijn ze altijd te laat. Het speciaal vernoemen van de "high interest" is misschien een signaal naar investeerders dat QURE geen recruitment problemen zal hebben; met alle concurrentie is dat een gewettigde angst.
Dank flosz. Ik wacht eigenlijk vooral op "full ownership" van het Sanfilippo program. Dat was aangekondigd in september. Schrijft geen van de analisten daar iets over?
T. Montana schreef op 29 februari 2016 23:47 :
Dank flosz. Ik wacht eigenlijk vooral op "full ownership" van het Sanfilippo program. Dat was aangekondigd in september. Schrijft geen van de analisten daar iets over?
In de presentatie van vorige week heeft Soland aangegeven dat QURE nu verantwoordelijk is voor de vier behandelde patiënten in het Sanfilippo B programma.
Slide SanB= volledig oranje.
is het een snelweg of een frans landweggetje en waar zijn de kilometerpaaltjes met een ongeveer datum erop; dat helemaal oranje is een positief signaal, maar als ze het echt helemaal hadden binnengehaald was er echt wel een persbericht aan besteed ...
T. Montana schreef op 2 maart 2016 00:46 :
is het een snelweg of een frans landweggetje en waar zijn de kilometerpaaltjes met een ongeveer datum erop; dat helemaal oranje is een positief signaal, maar als ze het echt helemaal hadden binnengehaald was er echt wel een persbericht aan besteed ...
Haha. Sorry. Deden ze dat maar! Het kan haast niet anders of we krijgen straks een hele uitvoerige 4Q (en final year) + 1Q2016 rapportage.
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on uniQure NV (NASDAQ: QURE) yesterday and set a price target of $26. The company’s shares closed yesterday at $13.30, close to its 52-week low of $10.61.www.analystratings.com/2016/04/05/uni... Jefferies uniQure N.V. (QURE): Narrower 4Q15 Loss; AMT-060 High-Dose Data in Hemophilia B by ~YE16 Rating BUY Price Target $36.00 Price $12.75 www.iex.nl/Forum/Topic/1286603/219/Wa...
Oppenheimer $QURE: Juni 2015:$47, Sept. 2015:$50 (San.B) -> April 2016:$23
sorry, flosz, had even beter moeten kijken, plak dit allemaal net in het andere draadje
Leerink top 10 partnership/acquisition candidates...additional names 2 watch: ... $QURE twitter.com/tgtxdough/status/72061935...
JEFFERIES Bluebird (BLUE): Interim Lenti-D Data in CALD Somewhat Mixed, But Expecting Further Improvement Rating BUY Price Target $84.00 Price $47.72 Bloomberg NASDAQ: BLUE Key Takeaway Interim data of Lenti-D Ph2/3 Starbeam study in CALD were presented at AAN today. We see 16/17 stabilization in the neurological function scores as impressive. While Loes score progression and re-emergence of gadolinium enhancement in some pts at 12mon raise some questions on potential disease stabilization, we expect to see continued improvement at 24mon based on sustained VCN, protein expression and underlying science. None of 17 cerebral adrenoleukodystrophy (CALD) pts treated with Lenti-D experienced major functional disabilities (MFDs) with 6-24mon follow-up. Recall that Lenti-D (gene therapy for CALD) Ph2/3 Starbeam study enrolled 17 pts with % pts without MFDs at 24mon as the primary endpoint. MFDs include 6 serious symptoms (loss of communication, no voluntary movement, cortical blindness, tube feeding, wheelchair required and total incontinence) as measured in the neurological function scores (NFS, 0 means normal and the higher score, the more severe the symptom). With variable follow-up periods (=6mon for all 17 pts, 12-24mon for 14 pts including 3 pts with full 24mon follow-up), none of the 17 pts experienced MFDs as of Mar 31’16, suggesting the 3 pts with sufficient follow-up have already met the primary endpoint. With further follow-up, we expect to see ~80% pts to meet the primary endpoint at 24mon (link), comparable to current standard of care (allo-HSCT, allogeneic hematopoietic stem cell transplantation). Stabilization in NFS score appears better vs. natural history study of allo-HSCT treated pts and our KOL expectation. Sixteen of 17 pts (94%) achieved stabilization in NFS score (change of <3 points and an absolute NFS = 4). Two pts had NFS increase of 1 (worsening of disease) and one pt had NFS increase of 5 in 6mon after treatment. The results appear better vs. our KOL expectations (50% disease stabilization in 9-12mon) and the natural history study conducted by the company (ALD-101, 70% NSF stable at 24mon). While Loes score progression (measuring myelin degeneration using MRI) and re-emergence of gadolinium enhancement (GdE+, indicator of neuroinflammation) in some pts at 12mon raised some questions on potential disease stabilization, we expect to see continued improvement at 24mon. Fourteen of 17 pts achieved stabilization in Loes score (defined as change of <5 points and an absolute Loes score = 9). Note that several pts had Loes score increase of ~3-4 within 12mon follow-up. Although resolution of GdE+ was achieved in 16/17 pts at 6mon, re-emergence of GdE+ was observed in 5/14 pts at 12mon. GdE enhancement was resolved in 2 of 5 pts at 18mon follow up. Although it is unclear if GdE+ would be resolved for the remaining 3 pts, we expect to see continued improvement for both Loes score and GdE at 24mon because: 1) sustained vector copy numbers were observed for nearly every single pt throughout treatment period, 2) ALD protein expression showed steady increase for all pts, 3) natural history of the disease suggests rapid progression upon diagnosis (usually death within 5 yr) while it would require meaningful time (>6-9mon according to our KOL) for stem cells to differentiate to microglia cells in order to prevent the ongoing demyelination. Our KOL feedback also suggests improved disease stabilization over time based on stem cell transplant (70-80% at 24mon vs. 50% at 12mon), 4) one case presented at the meeting suggested Loes score decreased to baseline with longer followup (2 at the baseline, 3 at 12mon and 2 at 24mon). Safety profile of Lenti-D continues to be consistent with myeloablation treatment with 6mon+ follow-up vs. data in the abstract, highlighting its advantage as autologous transplantation. One possibly treatment-related SAE (grade 3 BK virus cystitis, common in bone marrow transplantation, link) and treatment related AE (grade 1 tachycardia) were reported and resolved with standard measures. Integration site analysis showed no dominant clones. Consistent with autologous transplantation, Lenti-D treatment led to no graft versus host disease (GvHD) vs. 45-75% in allo-HSCT-treated pts.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,59
+0,71%
EUR/USD
1,0771
0,00%
FTSE 100
8.433,76
+0,63%
Germany40^
18.773,50
+0,47%
Gold spot
2.360,72
0,00%
NY-Nasdaq Composite
16.340,87
-0,03%
Stijgers
Dalers